Home›Search›MedComm - Oncology

MedComm - Oncology

John Wiley and Sons Inc · China · Est. 2022

ISSN2769-6448eISSN2769-6448

SJR Q3✓ WOS ESCI✓ Scopus / SJR✓ DOAJ✓ Open Access

/ 100

High Risk

Score Breakdown

✓ WoS ESCI+10

✓ Scopus Q3+12

✓ DOAJ Verified+15

Total37

Journal Impact Factor

This journal is indexed in Web of Science (JCR) and has an official Journal Impact Factor. View the current value on the journal’s page ↗

SJR Score

0.433

H-Index

CiteScore

View ↗

Scopus metric · on the journal’s page

Total Works

174

Total Citations

958

2yr Mean Citedness

4.58

Free JIF alternative

Aims & Scope✦ Inferred from recent articles

This journal focuses on the molecular mechanisms and therapeutic strategies related to cancer progression, drug resistance, and the tumor microenvironment. It covers topics such as cancer stem cells, epigenetic modifications, metabolic reprogramming, immune evasion, and the role of specific proteins and signaling pathways in tumorigenesis. The journal also explores novel therapeutic approaches including nanomedicine, molecular glues, and combination therapies, as well as the interplay between aging, comorbidities, and cancer.

AI-summarised from recent articles · verify on publisher page →

⚡ Speed vs Prestige

How does this journal balance review speed with impact level?

weeks to review

Average · median is 15 wks

SJR Rank

Top 75% in field

General Information

Country / RegionChina

Primary LanguageEnglish

1st Year Published2022

Annual Volume~ 47 articles / year

StatusActive (last: 2026)

Total Publications174

Publisher OrgWiley

OA Since2021

Visit Journal Website

Submission Info

Peer ReviewSingle-blind

Review Time~15 weeks

Acceptance Rate—

OA LicenseCC BY

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

Plagiarism Detection✓ Yes

📦 Long-term Preservation

PorticoCLOCKSS

Think.Check.Submit Compliance

thinkchecksubmit.org

10/12 · 83%

✅

Do you know the journal / publisher?

John Wiley and Sons Inc

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

2769-6448 / 2769-6448

✅

Indexed in a trusted database?

Scopus, DOAJ

✅

Peer review process documented?

Single-blind

❌

Follows ethical publishing standards (COPE)?

N/A

❌

APC fees clearly disclosed?

N/A

✅

Not on predatory/blacklists?

✓ Clean

✅

Long-term digital preservation?

Portico, CLOCKSS

✅

Plagiarism detection in place?

Yes

✅

Listed in DOAJ (verified OA)?

DOAJ verified

✅

Primary language documented?

English

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Times cited

2022

2023

2024

2025

2026

Source: OpenAlex · Note: citations accumulate over time so older years appear higher

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Biochemistry, Genetics and Molecular Biology (miscellaneous)Q3

OncologyQ3

Cancer ResearchQ4

Cell BiologyQ4

Subject Classification

Web of Science Categories

Oncology

Scopus Categories

Biochemistry, Genetics and Molecular Biology (miscellaneous)Cancer ResearchOncologyCell Biology

Research Topics (OpenAlex)

Cancer Immunotherapy and BiomarkersCancer Cells and MetastasisCancer, Hypoxia, and MetabolismCancer Research and TreatmentsEpigenetics and DNA MethylationNanoplatforms for cancer theranosticsProtein Degradation and InhibitorsCancer-related molecular mechanisms researchRNA modifications and cancerCAR-T cell therapy research